GSK work­ers may be in trou­ble with UK au­thor­i­ties; EU pledges €550M to fight AIDS, tu­ber­cu­lo­sis and malar­ia

6 years ago
News Briefing

Adap­ti­m­mune pledges $312M for Noile-Im­mune's T cell boost­ing tech in dri­ve to de­liv­er on TCR promise

6 years ago
Deals
Cell/Gene Tx

Bris­tol-My­ers opens up the Phase 0 path­way in test­ing its new can­cer ther­a­pies, fol­low­ing in Cel­gene’s foot­steps

6 years ago
Deals
R&D

GSK li­cens­es Ion­is' ex­per­i­men­tal hep B treat­ments in up to $262M deal

6 years ago
Deals

For sale: Boston Chil­dren’s team touts a new CRISPR de­liv­ery sys­tem for triple-neg­a­tive breast can­cer — plus — ...

6 years ago
R&D
Pharma

San­ther­a's Duchenne ef­fort gets a boost on pos­i­tive PhI­Ia for al­ter­na­tive steroid va­morolone — though there's a lot ...

6 years ago
R&D

Fran­chise killer: Are Re­gen­eron and Sanofi about to get hand­ed their walk­ing pa­pers on PC­SK9?

6 years ago
R&D

Cadre of gene-edit­ing biotechs ral­ly against al­ter­ing DNA that could af­fect fu­ture gen­er­a­tions

6 years ago
Cell/Gene Tx

Af­ter ink­ing a string of pipeline deals, Boehringer In­gel­heim is do­ing a makeover of the top ex­ec­u­tive team

6 years ago
People

Ok­la­homa judge finds J&J guilty for its role in the opi­oid epi­dem­ic — but shares spike on $572M fine

6 years ago
Pharma

ADC Ther­a­peu­tics signs pact with Freenome; Shang­hai Hen­lius Biotech eyes $600M for Hong Kong IPO

6 years ago
News Briefing

Out to shake up PC­SK9 mar­ket, Med­i­cines Co boasts of piv­otal PhI­II win for in­clisir­an

6 years ago
R&D

Lil­ly's Taltz wins third ap­proval, this time in pa­tients with ac­tive anky­los­ing spondyli­tis

6 years ago
Pharma

Fi­bro­Gen founder and CEO Thomas Neff dies un­ex­pect­ed­ly as lead drug nears com­mer­cial thresh­old

6 years ago
R&D

FDA to roll out mod­ern­iza­tion plan in push for da­ta in­ter­op­er­abil­i­ty

6 years ago
FDA+

From $30M launch round to $400M buy­out deal — with $250M up­front — in 10 short months

6 years ago
Deals
R&D

Top 20 by rev­enue: New analy­sis high­lights huge im­pact of tax re­form on many — but not all — of the top phar­ma ...

6 years ago
Pharma

Am­gen swoops in with $13.4B deal to pluck block­buster Ote­zla from Cel­gene

6 years ago
Deals

Olu­mi­ant from Lil­ly, In­cyte clears third eczema study, but who will use it?

6 years ago
R&D
Pharma

‘Ab­solute stand­out’ bio­phar­ma an­a­lyst Mark Schoenebaum has died

6 years ago
People

Pfiz­er, Astel­las win pri­or­i­ty re­view for Xtan­di sN­DA; Hemi­spherx changes its name

6 years ago
News Briefing

Igny­ta founder boosts team at his new can­cer start­up; Cy­tomx CMO hits the ex­it

6 years ago
Peer Review

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

6 years ago
Deals

FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

6 years ago
R&D
Pharma
First page Previous page 919920921922923924925 Next page Last page
A service from the Financial Times